Evidence map›Paper›PMID 33653950›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Inhibition of neuroinflammatory nitric oxide signaling suppresses glycation and prevents neuronal dysfunction in mouse prion disease.

Julie-Myrtille Bourgognon, Jereme G Spiers, Sue W Robinson, Hannah Scheiblich, Paul Glynn, Catharine Ortori, Sophie J Bradley, Andrew B Tobin, Joern R Steinert

Open access · hybridAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Neuroinflammation in Alzheimer disease.Nature reviews. Immunology · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Evaluation of the Influence ofMolecules (Basel, Switzerland) · 2024
    Article
  12. Review
  13. Article
  14. Article
  15. Heliyon · 2024
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Julie-Myrtille BourgognonCentre for Immunobiology, University of Glasgow, Glasgow, G12 8TA, United Kingdom.ORCID 0000-0001-6772-3965
Jereme G SpiersDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University, VIC 3083, Melbourne, Australia.ORCID 0000-0001-5872-8983
Sue W RobinsonMedical Research Council Toxicology Unit, University of Leicester, Leicester, LE1 9HN, United Kingdom.ORCID 0000-0002-4596-1978
Hannah ScheiblichDepartment of Neurodegenerative Disease and Geriatric Psychiatry/Neurology, University of Bonn, Bonn 53127, Germany.
Paul GlynnMedical Research Council Toxicology Unit, University of Leicester, Leicester, LE1 9HN, United Kingdom.ORCID 0000-0003-3055-5800
Catharine OrtoriSchool of Pharmacy, University of Nottingham, Nottingham NG7 2RD, United Kingdom.
Sophie J BradleyCentre for Translational Pharmacology, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, United Kingdom.
Andrew B TobinCentre for Translational Pharmacology, Veterinary and Life Sciences, University of Glasgow, Glasgow, G12 8QQ, United Kingdom.ORCID 0000-0002-1807-3123
Joern R SteinertSchool of Life Sciences, Queen's Medical Centre, University of Nottingham, Nottingham, NG7 2UH, United Kingdom joern.steinert@nottingham.ac.uk.ORCID 0000-0003-1640-0845
University of Glasgow · GBUniversity of Leicester · GBUniversity of Nottingham · GBLa Trobe University · AUUniversity of Bonn · DE

Funding

Medical Research Council MC_U132681855
6 · The paper itself

Abstract

Several neurodegenerative diseases associated with protein misfolding (Alzheimer's and Parkinson's disease) exhibit oxidative and nitrergic stress following initiation of neuroinflammatory pathways. Associated nitric oxide (NO)-mediated posttranslational modifications impact upon protein functions that can exacerbate pathology. Nonenzymatic and irreversible glycation signaling has been implicated as an underlying pathway that promotes protein misfolding, but the direct interactions between both pathways are poorly understood. Here we investigated the therapeutic potential of pharmacologically suppressing neuroinflammatory NO signaling during early disease progression of prion-infected mice. Mice were injected daily with an NO synthase (NOS) inhibitor at early disease stages, hippocampal gene and protein expression levels of oxidative and nitrergic stress markers were analyzed, and electrophysiological characterization of pyramidal CA1 neurons was performed. Increased neuroinflammatory signaling was observed in mice between 6 and 10 wk postinoculation (w.p.i.) with scrapie prion protein. Their hippocampi were characterized by enhanced nitrergic stress associated with a decline in neuronal function by 9 w.p.i. Daily in vivo administration of the NOS inhibitor L-NAME between 6 and 9 w.p.i. at 20 mg/kg prevented the functional degeneration of hippocampal neurons in prion-diseased mice. We further found that this intervention in diseased mice reduced 3-nitrotyrosination of triose-phosphate isomerase, an enzyme involved in the formation of disease-associated glycation. Furthermore, L-NAME application led to a reduced expression of the receptor for advanced glycation end-products and the diminished accumulation of hippocampal prion misfolding. Our data suggest that suppressing neuroinflammatory NO signaling slows functional neurodegeneration and reduces nitrergic and glycation-associated cellular stress.

Indexed as

Signal TransductionAnimalsCA1 Region, HippocampalMiceMice, TransgenicNeuronsNitric OxidePrion DiseasesNitric Oxideglycationneurodegenerationneuroinflammationnitric oxideprion aggregation

Identifiers

PMID33653950
PMCPMC7958397
OpenAlexW3134891588

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.